Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Lay Description
This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Chemotherapy drugs, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.
Category
- Cancers and Other Neoplasms
- Acute Lymphoblasic Leukemia
- IRB Number
- 20120250HU
- NCT Number
- NCT02883049
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Between 1 Year and 31 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Virginia Diaz
(210) 562-9149
diazvr@uthscsa.edu
Principal Investigator
Anne-Marie Langevin